Prevalence and risk factors for metabolic-associated fatty liver disease in adult participants attending tertiary hospitals in Dodoma, Tanzania. This was a cross-sectional study

Author:

Msagati Francis1,Alphonce Baraka1,Sindato Emmanuel1

Affiliation:

1. University Dodoma

Abstract

Abstract

Introduction: Metabolic-associated fatty liver disease (MAFLD) is a rapidly growing public health concern due to its association with metabolic disorders and liver-related complications. There is paucity of data on the burden of MAFLD in Tanzania. The aim of this study was to assess the prevalence and associated factors of MAFLD among adult participants in Dodoma, Tanzania, who are critical for designing preventive strategies. We evaluated the associations between MAFLD and several factors, including age, sex, lifestyle, type 2 diabetes, hypertension, dyslipidemia and obesity. Methods A total of 351 adult participants were recruited from October 2023 to March 2024 at tertiary hospitals. The diagnosis of MAFLD was established based on evidence of steatohepatitis on imaging plus any one of five cardiometabolic risk factors, such as overweight or obesity (BMI ≥ 25 kg/m2), diabetes mellitus type 2, hypertension, dyslipidemia, and metabolic syndrome (combination of three or more of the above). Demographic, clinical, and metabolic marker data were collected and analyzed to identify potential risk factors associated with MAFLD. The chi-squared test was used to analyze categorical data. Logistic regression analysis was used to check for associated factors; significance was defined as a p value < 0.05. The UDOM research and publication committee approved the study, and informed consent was obtained from the participants and in-participants aged older than 18 years with metabolic conditions. Results A total of 351 participants were recruited, of whom 53% were females, and the median age was 62 (IQR 52–70) years, with most of the participants residing in urban areas (242, 68.9%). The study prevalence of MAFLD was 21.9%. Significant fibrosis was defined as a FIB-4 index ≥ 1.3 in 14% of MAFLD patients who were found to have advanced fibrosis. Diabetes mellitus (OR: 3.9; 95% CI (2.1–7.2, p < 0.000), dyslipidemia (OR: 2.3; 95% CI 1.2–4.7, p = 0.013), central obesity (OR: 2.0; 95% CI (1.1–3.7; p = 0.016), lifestyle factors (OR: 2.6; 95% CI (1.4–4.8; p = 0.001), smoking (OR: 2.6; 95% CI (1.4–4.8; p = 0.001) and lack of exercise (OR: 2.3; 95% CI (1.2–4.2; p = 0.005)) were independently associated with MAFLD. Conclusion This study revealed a significant frequency of MAFLD and significant associations with established risk factors such as diabetes, smoking, alcohol consumption, lack of exercise, central obesity, and dyslipidemia. These findings highlight the importance of early identification and management of these risk factors to prevent MAFLD and its associated complications. Future research should focus on understanding causal mechanisms and evaluating interventions for preventing MAFLD development in at-risk populations attending tertiary hospitals.

Publisher

Springer Science and Business Media LLC

Reference53 articles.

1. The Global Burden of Liver Disease;Younossi ZM;Clin Gastroenterol Hepatol,2023

2. EBioMedicine What the New De fi nition of Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) Left Behind: Genetically Acquired Fatty Liver Disease;Bril F;EBioMedicine,2021

3. Expert Opinion A new de fi nition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement;Eslam M;J Hepatol,2020

4. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K et al. AASLD PRACTICE GUIDELINE The Diagnosis and Management of Non-Alcoholic Fatty Liver Disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Assoc. 2012;:2005–23.

5. From MAFLD to hepatocellular carcinoma and everything in between;Bae SDW;Chin Med J (Engl),2022

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3